From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) [1] .
EWP 815 is a disulfiram analogue, is a potent inhibitor of Ins(1,4)P2 phosphatase and Ins(1,4,5)P3 5-phosphatase. EWP 815 also inhibits enzyme dopamine β-hydroxylase activity [1] .
D-myo-Inositol 1,4,5-trisphosphate hexapotassium salt is the hexapotassium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
D-myo-Inositol-1,4,5-triphosphate sodium salt is the hexapotassium salt of D-myo-Inositol 1,4,5-trisphosphate (1,4,5-IP3), which is a second messenger that stimulates the discharge of calcium from the endoplasmic reticulum.
KIRA9 is a potent IRE1 inhibitor (IC50=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis[1].
GNF362 is a selective, potent, and orally bioavailable inhibitor of inositol trisphosphate 3’ kinase B (Itpkb) with an IC50 of 9 nM. GNF362 also inhibits Itpka and Itpkc with IC50 values of 20 nM and 19 nM, respectively. Inositol trisphosphate 3’ kinase B (Itpkb) is a Ca 2+-dependent kinase, which phosphorylates the 3’ position of Ins (1,4,5) P3 to generate inositol 1,3,4,5-tetrakisphosphate [Ins (1,3,4,5) P4] [1].
NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research [1] .
KV2 channel inhibitor-1 is a selective KV2 channel inhibitor with IC50s of 0.2 μM and 0.41 μM for KV2.1 and KV2.2, respectively. KV2 channel inhibitor-1 possesses good selectivity over KV1.2 (IC50>10 μM). KV2 channel inhibitor-1 is >10-fold selective over NaV channels and other KV channels and displays weak activity on CaV channels [1].
DPP-4-IN-3 (Compound 5a) is a potent dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 0.75 nM. DPP-4-IN-3 shows excellent antioxidant and insulinotropic activity [1].
N-Arachidonoyl Taurine is an activator of the transient receptor potential vanilloid TRPV1 and TRPV4, with EC50s value of 28 μM and 21 μM, respectively [1].
FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes [1] .
JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1(FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity [1].
GKA50 is a potent glucokinase activator (EC50=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca 2+-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats [1] .
GKA50 quarterhydrate is a potent glucokinase activator (EC50=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca 2+-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats [1] .
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes [1].
IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes [1].
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) [1] .
FOXM1 is an important transcription factor that controls cell cycle gene expression critical for DNA replication and mitosis, underscoring its critical role in cellular processes. In addition to cell proliferation, FOXM1 contributes to DNA break repair and DNA damage checkpoint responses. FOXM1 Protein, Human (His, SUMO-Myc) is the recombinant human-derived FOXM1 protein, expressed by E. coli , with N-10*His, C-Myc, N-SUMO labeled tag. The total length of FOXM1 Protein, Human (His, SUMO-Myc) is 93 a.a., with molecular weight of ~31.2 kDa.
Insulin-1, a vital regulator of glucose, efficiently reduces blood glucose by enhancing cellular permeability to monosaccharides, amino acids, and fatty acids. Its actions span glycolysis acceleration, pentose phosphate cycle promotion, and liver glycogen synthesis facilitation. Structurally, Insulin-1 is a heterodimer with A and B chains linked by two disulfide bonds, emphasizing its pivotal role in coordinating metabolic processes crucial for glucose homeostasis. Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His, solution) is the recombinant mouse-derived Insulin-1/Ins1 protein, expressed by P. pastoris , with N-His, C-Myc labeled tag. The total length of Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His, solution) is 84 a.a., with molecular weight of ~25 kDa.
Insulin-1 is an important regulator of glucose and can effectively lower blood sugar by increasing cellular permeability to simple sugars, amino acids, and fatty acids. Its effects include accelerating glycolysis, promoting pentose phosphate cycle, and promoting hepatic glycogen synthesis. Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His) is the recombinant mouse-derived Insulin-1/Ins1 protein, expressed by P. pastoris , with C-Myc, N-6*His labeled tag. The total length of Insulin-1/Ins1 Protein, Mouse (P.pastoris, Myc, His) is 84 a.a., with molecular weight (affected by relative charge) of 29 KDa.
MINPP1 Protein, a dual-function phosphatase, regulates inositol pentakisphosphate (InsP5) and inositol hexakisphosphate (InsP6) levels through phosphoinositide 5- and phosphoinositide 6-phosphatase activity. It also acts as a 2,3-bisphosphoglycerate 3-phosphatase, crucial for bone development and chondrocyte transition. By controlling intracellular inositol polyphosphates, MINPP1 potentially influences cation homeostasis, impacting neural cell signaling through free cation availability. MINPP1 Protein, Human (HEK293, His) is the recombinant human-derived MINPP1 protein, expressed by HEK293, with C-6*His labeled tag. The total length of MINPP1 Protein, Human (HEK293, His) is 457 a.a., with molecular weight of ~56.0 kDa.
